Jacqueline M Kraveka DO

Summary

• Dr. Kraveka is a Professor of Pediatrics and a Pediatric Hematologist-Oncologist at the Medical University of South Carolina (MUSC) in Charleston, SC. Born in Velasco, Cuba, she immigrated to the United States at the age of four. Dr. Kraveka received her undergraduate degree from Columbia University in 1989 and her medical degree from Nova Southeastern University College of Osteopathic Medicine in 1994. She completed her residency in pediatrics at Miami Children’s Hospital in 1997, followed by a fellowship in pediatric hematology oncology at MUSC in 2000.
  
  Dr. Kraveka has been recognized by Castle Connolly as a “Top Doctor,” “Exceptional Woman in Medicine,” and “Top Hispanic & Latino Doctor.”
  
  Her clinical practice is focused on pediatric oncology, with specific interests in neuroblastoma, pediatric sarcomas, precision medicine, and clinical trial development. She has extensive experience in designing and leading pediatric oncology clinical trials and serves as a key leader in in the field as a member of both the Executive Board and Scientific Committee for the Beat Childhood Cancer Research Consortium (BCC). Dr. Kraveka was part of the core BCC team that designed and conducted the pivotal clinical trials leading to the FDA approval of IWILFIN™ (eflornithine) in December 2023—the first oral maintenance therapy approved to reduce the risk of relapse in patients with high-risk neuroblastoma.
  
  She also serves as the Institutional Principal Investigator for Children’s Oncology Group and BCC clinical trials at MUSC. Beyond clinical research, Dr. Kraveka is engaged in translational and bench research, with a focus on sphingolipid-mediated therapies in pediatric cancer. Her long-term goal is to develop safer, more effective treatments to improve outcomes for children with cancer.